• Deccan Chronicle
  • Andhra Bhoomi
  • Asian Age
  • ePaper
  •  Auto Refresh
Home

ePaper
Last Updated:01:54 PM IST | Monday, Aug 08, 2022
  • Home
  • Politics, Plan And Policy
  • Markets
  • Companies
  • Economy
  • In Other News
  • Autos
  • Just In
Menu
  • Home
  • Politics, Plan And Policy
  • Markets
  • Companies
  • Economy
  • In Other News
  • Autos
  • Just In
Home > Economy > Frequent FDA visits slow down pharma exports: GV Prasad
Economy
Frequent FDA visits slow down pharma exports: GV Prasad
By  
DECCAN CHRONICLE.   , Published : Nov 19, 2019, 2:06 am IST | Updated : Nov 19, 2019, 2:06 am IST

It (effect of frequent inspections) is quite significant (on India pharma exports): GV Prasad.

Dr Reddy’s Labs
Dr Reddy’s Labs

Hyderabad: Indian pharmaceutical companies, over the last few years, have witnessed frequent inspection from US FDA and other European regulatory bodies due to its alleged lax standards in the production facilities across the country. Now, in a stark admission, Dr Reddy’s Labs’ Managing Director G.V. Prasad said that such inspections and subsequent observations not only slows down the growth of pharma exports from the country, but also hurt the companies’ possibility to attract business from China due to the raging trade war between the world’s largest two economies.

“It (effect of frequent inspections) is quite significant (on India pharma exports). Part of the slowdown is that. Lot of companies' approvals have stalled because of warning letters. That has affected the new product introductions and growth,” he said in a press briefing on Monday.

“Everybody should up their game in terms of quality, systems, discipline, and integrity of data. All there are important things for the industry,” he added.

Citing the raging US-China trade war, Mr Prasad reiterated that improved standards will also help Indian pharma companies as westerm companies are thinking of reducing their dependency on China, a major source of APIs and chemical intermediaries.  “That (the situation) opens up an opportunity for India. China as a nation is moving towards more innovation and getting out of what they perceive as low value-added business. That is the opportunity which is opening up for India. And China itself is a great market,” he said.

end-of
Tags: 
indian pharmaceutical companies, us fda, dr reddy’s labs
Location: 
India, Telangana, Hyderabad
Latest From Economy
Former RBI governor Urjit Patel has written a book titled Overdraft: Saving the Indian Saver.

Urjit Patel: Why our banks aren't saviours of the Indian saver

FIEO Director General Ajay Sahai said the global situation is likely to improve in the first half of 2020, which would have a positive impact on India's exports.

Exports to rebound in 2020 but growth to remain subdued

ICRA Economist Aditi Nayar expects moderation in vegetable prices to a large extent by early 2020. (Photo: File)

Inflation leaves consumers teary-eyed as pricey onions, food items bite

Most Popular

Mukesh Ambani 9th richest on Forbes' real-time billionaires list
Top credit card myths harmful for your financial well-being
Microsoft CEO Satya Nadella tops Fortune's Businessperson of the Year 2019
Employment growth slowed down in last two years: report
GST structure: key challenges and its solutions

Editor's Picks

Income tax e-filers drop by over 6.6 lakh in FY19: Official data
Swiping on your smartphone reveals a lot about you to your social media company
  • Read Financial Chronicle as it appears in print.
  • Subscribe, and get it delivered in the inbox everyday.
  • Politics, Plan And Policy
  • Markets
  • Companies
  • Economy
  • In Other News
  • Autos
  • Just In
  • Home
  • About Us
  • Contact Us
  • Terms of Service
  • Privacy Guidelines
  • Copyright © 2019 Financial Chronicle, All rights reserved
Developed & Maintained By Daksham